Loading news...
Torex Gold Resources Inc. (TSE: TXG - Get Free Report)'s share price crossed above its 200-day moving average during trading on Monday. The stock has a 200-day moving average of C$58.31 and traded as high as C$68.13. Torex Gold Resources shares last traded at C$64.10, with a volume of 984,778 shares changing hands. Wall Street
10x Genomics (NASDAQ: TXG - Get Free Report) and Azenta (NASDAQ: AZTA - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, dividends, valuation and analyst recommendations. Profitability This table compares 10x Genomics and Azenta's net
SG Americas Securities LLC trimmed its stake in shares of 10x Genomics (NASDAQ: TXG) by 50.3% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 39,799 shares of the company's stock after selling 40,241 shares during the period. SG Americas Securities LLC's holdings
PLEASANTON, Calif., Jan. 22, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced it will report financial results for the fourth quarter and full year ended December 31, 2025 after market close on Thursday, February 12, 2026.
Medical Info Systems rides AI and telehealth tailwinds, lifting DOCS, TXG and OMCL, but cyber risks and industry underperformance keep optimism in check.
Inscription Capital LLC grew its holdings in shares of 10x Genomics (NASDAQ: TXG) by 161.6% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 96,014 shares of the company's stock after purchasing an additional 59,305 shares during the period.
Cathie Wood's Ark Invest unveiled its "big ideas" for 2025 in a cryptic list, challenging users to interpret a series of custom images called "ARKmoji" to understand their picks for the year.
Study aims to identify single cell immune signatures of disease activity and treatment response to support clinical care PLEASANTON, Calif., Jan. 12, 2026 /PRNewswire/ -- 10x Genomics, Inc.
Collaboration with Dana-Farber Cancer Institute aims to identify biomarkers linked to treatment response for the next generation of cancer therapies and to define a clinical reporting framework to power precision oncology 10x also plans to establish a CLIA-certified laboratory to enable development of future innovative diagnostic tests PLEASANTON, Calif., Jan. 12, 2026 /PRNewswire/ -- 10x Genomics, Inc.
Multi-phase initiative will generate single cell and spatial data from over 20,000 samples across leading immuno-oncology laboratories to map the immune landscape of cancer and drive the next generation of immunotherapies and vaccine discovery PLEASANTON, Calif., Jan. 12, 2026 /PRNewswire/ -- 10x Genomics, Inc.
PLEASANTON, Calif., Jan. 11, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced preliminary, unaudited select results for the fourth quarter and full year ended December 31, 2025.
Torex Gold Resources Inc. (TSE: TXG - Get Free Report)'s stock price crossed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of C$54.40 and traded as high as C$69.45. Torex Gold Resources shares last traded at C$69.45, with a volume of 397,116 shares trading hands. Analysts Set
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced a strategic collaboration with 10x Genomics (Nasdaq: TXG), a leader in single cell and spatial biology, to establish ImmuneScape™, a multiomics research initiative designed by CareDx to eluci.
10x Genomics (NASDAQ: TXG - Get Free Report) and United Treatment Centers (OTCMKTS:POTN - Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends and analyst recommendations. Valuation and Earnings This table compares 10x
Financial Consulate Inc. bought a new position in shares of 10x Genomics (NASDAQ: TXG) during the undefined quarter, according to its most recent 13F filing with the SEC. The firm bought 156,457 shares of the company's stock, valued at approximately $1,829,000. Financial Consulate Inc. owned 0.13% of 10x Genomics as of its most
/PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will present
10x Genomics (NASDAQ: TXG - Get Free Report) and iRhythm Technologies (NASDAQ: IRTC - Get Free Report) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations. Profitability This table compares 10x Genomics and
Aaron Wealth Advisors LLC purchased a new position in shares of 10x Genomics (NASDAQ: TXG) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 39,530 shares of the company's stock, valued at approximately $462,000. Other large investors also recently bought and sold
Torex Gold Resources Inc. (TSE: TXG - Get Free Report) crossed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of C$52.17 and traded as high as C$65.02. Torex Gold Resources shares last traded at C$64.75, with a volume of 502,160 shares. Analyst Upgrades and Downgrades A number
Federated Hermes Inc. raised its holdings in shares of 10x Genomics (NASDAQ: TXG) by 665.6% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 787,522 shares of the company's stock after acquiring an additional 684,659 shares during